Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing

212
83
Favorite

Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing

Motley Fool2021-06-11

As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: "It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

212

Report

Comment（83）

Vincxie
·2021-06-30
Agrees
Reply
Like
Report
sUs
·2021-06-11
Agreed...
Reply
Like
Report
飞天神鼠
·2021-06-11
Really
Reply
Like
Report
飞天神鼠
·2021-06-11
Follow
Reply
Like
Report
Meshaarias72
·2021-06-11
Like n comment pls
Reply
2
Report
Fold Replies
- 可乐Coke:
  ok
  2021-06-12
  Reply
  Report
GLSC
·2021-06-11
theoretically easy but when emotion kicks in...... story line changed
Reply
1
Report
Fold Replies
- Meshaarias72:
  Y
  2021-06-11
  Reply
  Report
Longshot
·2021-06-11
Nice
Reply
1
Report
BoonHuat
·2021-06-11
Good advice!
Reply
Like
Report
Chuashiyong
·2021-06-11
Really?
Reply
3
Report
Fold Replies
- SafetyFirst:
  comment
  2021-06-13
  Reply
  Report
- Chuashiyong:
  Thanks
  2021-06-12
  Reply
  Report
- Meshaarias72:
  Yy
  2021-06-11
  Reply
  Report
AudreyWong
·2021-06-11
Good advice
Reply
2
Report
Fold Replies
- Meshaarias72:
  Y
  2021-06-11
  Reply
  Report
JunJie
·2021-06-11
Is it so easy?
Reply
2
Report
Fold Replies
- Meshaarias72:
  Y
  2021-06-11
  Reply
  Report
Rama_Lion
·2021-06-11
Everyone knows but hard to follow !!
Reply
1
Report
Weiyuan
·2021-06-11
Nice. To the moon.
Reply
1
Report
Fold Replies
- Meshaarias72:
  Yy
  2021-06-11
  Reply
  Report
Errloy
·2021-06-11
Pls like and comment thanks! ??
Reply
2
Report
Fold Replies
- Errloy:
  Thanks!
  2021-06-11
  Reply
  Report
- SKLow:
  done.
  pls like back tq
  2021-06-11
  Reply
  Report
- AQJP:
  done
  2021-06-11
  Reply
  Report
Kok
·2021-06-11
Pls like n comment. Tks!
Reply
1
Report
Fold Replies
- Kok:
  sure
  2021-06-11
  Reply
  Report
- Errloy:
  Done :) Pls reply too!
  2021-06-11
  Reply
  Report
Daveb
·2021-06-11
Its easy. Only buy GME AND AMC.. up over 2000% so far this year... no other stock comes close . ??✊?✊????
Reply
3
Report
MireyaMiya万亿丰
·2021-06-11
Choose to buy S&P500 ETF...safer. Always see green green..
Reply
2
Report
Weeckee
·2021-06-11
Speculation with no fundamental is like gaming. Win or loss.. most of the time loose
Reply
3
Report
DJJJ
·2021-06-11
Totally agree with this article! Just like Buffer who loves saying this -"Get rich slowly" [美金]
Reply
2
Report
vivo8787
·2021-06-11
Likes
Reply
2
Report
Fold Replies
- vivo8787:
  Thanks
  2021-06-11
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2142221222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-11 11:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2142221222","market":"us","top_or_hot":-1,"title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","media":"Motley Fool","content":"<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXCM","symbol_name":"德康医疗","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","article_id":"2142221222","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","pubTimestamp":1623380520,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Get-rich-quick strategies rarely work.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"translate_title":"在股市赚钱很容易--如果你避免这一件事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXCM":0.9,"OCGN":0.9},"content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":153376036,"gmtCreate":1625011863025,"gmtModify":1703849970226,"author":{"id":"3580183572660250","authorId":"3580183572660250","name":"Vincxie","avatar":"https://static.tigerbbs.com/638af725e5e95ef7d2e629a3a49b0690","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":2,"crmLevelSwitch":1,"idStr":"3580183572660250","authorIdStr":"3580183572660250"},"htmlText":"Agrees&nbsp;","listText":"Agrees&nbsp;","text":"Agrees","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/153376036","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188978747,"gmtCreate":1623420581489,"gmtModify":1704203221880,"author":{"id":"3574914161995189","authorId":"3574914161995189","name":"sUs","avatar":"https://static.tigerbbs.com/20333dcc0f0c43df9ba7c18ce429ae93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574914161995189","authorIdStr":"3574914161995189"},"htmlText":"Agreed...&nbsp;","listText":"Agreed...&nbsp;","text":"Agreed...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188978747","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188060754,"gmtCreate":1623416547378,"gmtModify":1704203023788,"author":{"id":"3562564487802138","authorId":"3562564487802138","name":"飞天神鼠","avatar":"https://static.tigerbbs.com/d7b258e8e42a780bde477c48b8767f73","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3562564487802138","authorIdStr":"3562564487802138"},"htmlText":"Really","listText":"Really","text":"Really","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188060754","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188060105,"gmtCreate":1623416533507,"gmtModify":1704203022816,"author":{"id":"3562564487802138","authorId":"3562564487802138","name":"飞天神鼠","avatar":"https://static.tigerbbs.com/d7b258e8e42a780bde477c48b8767f73","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3562564487802138","authorIdStr":"3562564487802138"},"htmlText":"Follow","listText":"Follow","text":"Follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188060105","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":188060307,"gmtCreate":1623416526309,"gmtModify":1704203022655,"author":{"id":"3577781617271173","authorId":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577781617271173","authorIdStr":"3577781617271173"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188060307","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4702700,"gmtCreate":1623464994279,"gmtModify":1663228539642,"authorId":3582270537906794,"author":{"id":3582270537906794,"idStr":"3582270537906794","authorId":3582270537906794,"name":"可乐Coke","avatar":"https://static.tigerbbs.com/ad7deb4e9a6dac53889160d4c9fab864","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":188060307,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":188080313,"gmtCreate":1623416152732,"gmtModify":1704203009135,"author":{"id":"3582104380923924","authorId":"3582104380923924","name":"GLSC","avatar":"https://static.tigerbbs.com/639bc9d41aaded264f9846e1842f819a","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582104380923924","authorIdStr":"3582104380923924"},"htmlText":"theoretically easy but when emotion kicks in...... story line changed","listText":"theoretically easy but when emotion kicks in...... story line changed","text":"theoretically easy but when emotion kicks in...... story line changed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/188080313","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4688325,"gmtCreate":1623416536709,"gmtModify":1663228472258,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":188080313,"type":1,"supId":0,"prevId":0,"content":"Y","text":"Y","html":"Y"}],"langContent":"EN"},{"id":188017288,"gmtCreate":1623416120844,"gmtModify":1704203008002,"author":{"id":"3570092809336734","authorId":"3570092809336734","name":"Longshot","avatar":"https://static.tigerbbs.com/7cad4ddeab0622dd29ed1d7c76c750b8","vip":1,"hat":"https://static.tigerbbs.com/306aa047bc14b6942cda1aed925cf8c3","crmLevel":7,"crmLevelSwitch":0,"idStr":"3570092809336734","authorIdStr":"3570092809336734"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188017288","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181733740,"gmtCreate":1623410798980,"gmtModify":1704202850330,"author":{"id":"3574549633778650","authorId":"3574549633778650","name":"BoonHuat","avatar":"https://static.tigerbbs.com/f64154b666040668c472fc3731becde7","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3574549633778650","authorIdStr":"3574549633778650"},"htmlText":"Good advice!","listText":"Good advice!","text":"Good advice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181733740","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181730495,"gmtCreate":1623410669917,"gmtModify":1704202847731,"author":{"id":"3583746694648290","authorId":"3583746694648290","name":"Chuashiyong","avatar":"https://static.tigerbbs.com/33a41b1f21be0461f133b575331eaf5b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583746694648290","authorIdStr":"3583746694648290"},"htmlText":"Really?","listText":"Really?","text":"Really?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181730495","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4722650,"gmtCreate":1623556236634,"gmtModify":1663228634939,"authorId":3570965583958757,"author":{"id":3570965583958757,"idStr":"3570965583958757","authorId":3570965583958757,"name":"SafetyFirst","avatar":"https://static.tigerbbs.com/a6356c1a4c82b1755621f3b2631a6784","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181730495,"type":1,"supId":0,"prevId":0,"content":"<u>comment</u>","text":"<u>comment</u>","html":"<u>comment</u>"},{"id":4712651,"gmtCreate":1623505748284,"gmtModify":1663228585866,"authorId":3583746694648290,"author":{"id":3583746694648290,"idStr":"3583746694648290","authorId":3583746694648290,"name":"Chuashiyong","avatar":"https://static.tigerbbs.com/33a41b1f21be0461f133b575331eaf5b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181730495,"type":1,"supId":0,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4688330,"gmtCreate":1623416554380,"gmtModify":1663228472748,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181730495,"type":1,"supId":0,"prevId":0,"content":"Yy","text":"Yy","html":"Yy"}],"langContent":"EN"},{"id":181459451,"gmtCreate":1623408399373,"gmtModify":1704202785841,"author":{"id":"3572753419106782","authorId":"3572753419106782","name":"AudreyWong","avatar":"https://static.tigerbbs.com/40785b46ddfde8e3d1c75100e369e110","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3572753419106782","authorIdStr":"3572753419106782"},"htmlText":"Good advice","listText":"Good advice","text":"Good advice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181459451","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4688332,"gmtCreate":1623416559892,"gmtModify":1663228474534,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181459451,"type":1,"supId":0,"prevId":0,"content":"Y","text":"Y","html":"Y"}],"langContent":"EN"},{"id":181423446,"gmtCreate":1623408057285,"gmtModify":1704202773848,"author":{"id":"3554034677029324","authorId":"3554034677029324","name":"JunJie","avatar":"https://static.tigerbbs.com/f716c717e7ddcae5f5912cad93972634","vip":1,"hat":"https://static.tigerbbs.com/1c1eed764d9c7ff83dc093fbb9a96bc2","crmLevel":5,"crmLevelSwitch":1,"idStr":"3554034677029324","authorIdStr":"3554034677029324"},"htmlText":"Is it so easy?","listText":"Is it so easy?","text":"Is it so easy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181423446","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4688336,"gmtCreate":1623416567091,"gmtModify":1663228474544,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181423446,"type":1,"supId":0,"prevId":0,"content":"Y","text":"Y","html":"Y"}],"langContent":"EN"},{"id":181416949,"gmtCreate":1623406445681,"gmtModify":1704202736004,"author":{"id":"3586400768244257","authorId":"3586400768244257","name":"Rama_Lion","avatar":"https://static.tigerbbs.com/d46e8e346504a8c42475e77a8f33e347","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586400768244257","authorIdStr":"3586400768244257"},"htmlText":"Everyone knows but hard to follow !!","listText":"Everyone knows but hard to follow !!","text":"Everyone knows but hard to follow !!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181416949","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181405864,"gmtCreate":1623405067058,"gmtModify":1704202699989,"author":{"id":"3554204111148142","authorId":"3554204111148142","name":"Weiyuan","avatar":"https://static.tigerbbs.com/4ecf0ca755ca05ad14390dacc9d51f43","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3554204111148142","authorIdStr":"3554204111148142"},"htmlText":"Nice. To the moon.","listText":"Nice. To the moon.","text":"Nice. To the moon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181405864","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4688337,"gmtCreate":1623416577561,"gmtModify":1663228473743,"authorId":3577781617271173,"author":{"id":3577781617271173,"idStr":"3577781617271173","authorId":3577781617271173,"name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181405864,"type":1,"supId":0,"prevId":0,"content":"Yy","text":"Yy","html":"Yy"}],"langContent":"EN"},{"id":181408565,"gmtCreate":1623404882857,"gmtModify":1704202696271,"author":{"id":"3576587122175675","authorId":"3576587122175675","name":"Errloy","avatar":"https://static.tigerbbs.com/f503564d233a06b4f9099253c032162f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576587122175675","authorIdStr":"3576587122175675"},"htmlText":"Pls like and comment thanks! ??","listText":"Pls like and comment thanks! ??","text":"Pls like and comment thanks! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/181408565","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4686695,"gmtCreate":1623411958767,"gmtModify":1663228464937,"authorId":3576587122175675,"author":{"id":3576587122175675,"idStr":"3576587122175675","authorId":3576587122175675,"name":"Errloy","avatar":"https://static.tigerbbs.com/f503564d233a06b4f9099253c032162f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181408565,"type":1,"supId":4684756,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"},{"id":4685518,"gmtCreate":1623408663100,"gmtModify":1663228461236,"authorId":3582927789816025,"author":{"id":3582927789816025,"idStr":"3582927789816025","authorId":3582927789816025,"name":"SKLow","avatar":"https://static.tigerbbs.com/b3aeaabd2ee1ec9afcdda5a4aab1994c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181408565,"type":1,"supId":0,"prevId":0,"content":"done.<br>\npls like back tq","text":"done.<br>\npls like back tq","html":"done.<br>\npls like back tq"},{"id":4684756,"gmtCreate":1623406167895,"gmtModify":1663228456034,"authorId":3573963808701301,"author":{"id":3573963808701301,"idStr":"3573963808701301","authorId":3573963808701301,"name":"AQJP","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181408565,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":181401587,"gmtCreate":1623404797749,"gmtModify":1704202694970,"author":{"id":"3560204717545571","authorId":"3560204717545571","name":"Kok","avatar":"https://static.tigerbbs.com/efc25bb5380f85af49509ed68d9a3d8f","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3560204717545571","authorIdStr":"3560204717545571"},"htmlText":"Pls like n comment. Tks!","listText":"Pls like n comment. Tks!","text":"Pls like n comment. Tks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/181401587","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4684305,"gmtCreate":1623404937820,"gmtModify":1663228453635,"authorId":3560204717545571,"author":{"id":3560204717545571,"idStr":"3560204717545571","authorId":3560204717545571,"name":"Kok","avatar":"https://static.tigerbbs.com/efc25bb5380f85af49509ed68d9a3d8f","vip":1,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.18","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2007},"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181401587,"type":1,"supId":4684279,"prevId":0,"content":"<u>sure</u>","text":"<u>sure</u>","html":"<u>sure</u>"},{"id":4684279,"gmtCreate":1623404839285,"gmtModify":1663228452749,"authorId":3576587122175675,"author":{"id":3576587122175675,"idStr":"3576587122175675","authorId":3576587122175675,"name":"Errloy","avatar":"https://static.tigerbbs.com/f503564d233a06b4f9099253c032162f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181401587,"type":1,"supId":0,"prevId":0,"content":"Done :) Pls reply too!","text":"Done :) Pls reply too!","html":"Done :) Pls reply too!"}],"langContent":"EN"},{"id":181543269,"gmtCreate":1623403648951,"gmtModify":1704202664892,"author":{"id":"3575141057639271","authorId":"3575141057639271","name":"Daveb","avatar":"https://static.tigerbbs.com/61df162e1597f1b5a6a6bfb13d7d92f5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575141057639271","authorIdStr":"3575141057639271"},"htmlText":"Its easy. Only buy GME AND AMC.. up over 2000% so far this year... no other stock comes close . &nbsp;??✊?✊????","listText":"Its easy. Only buy GME AND AMC.. up over 2000% so far this year... no other stock comes close . &nbsp;??✊?✊????","text":"Its easy. Only buy GME AND AMC.. up over 2000% so far this year... no other stock comes close . ??✊?✊????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181543269","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181558043,"gmtCreate":1623403245282,"gmtModify":1704202653193,"author":{"id":"3580082297864003","authorId":"3580082297864003","name":"MireyaMiya万亿丰","avatar":"https://community-static.tradeup.com/news/1124aa19e932df4e4bb55e398ab6f78a","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3580082297864003","authorIdStr":"3580082297864003"},"htmlText":"Choose to buy S&amp;P500 ETF...safer. Always see green green..","listText":"Choose to buy S&amp;P500 ETF...safer. Always see green green..","text":"Choose to buy S&P500 ETF...safer. Always see green green..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181558043","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181524144,"gmtCreate":1623402946188,"gmtModify":1704202645736,"author":{"id":"3582072953259355","authorId":"3582072953259355","name":"Weeckee","avatar":"https://static.itradeup.com/news/fa7604d9be05bbf456327176402c13a9","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"3582072953259355","authorIdStr":"3582072953259355"},"htmlText":"Speculation with no fundamental is like gaming. Win or loss.. most of the time loose","listText":"Speculation with no fundamental is like gaming. Win or loss.. most of the time loose","text":"Speculation with no fundamental is like gaming. Win or loss.. most of the time loose","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181524144","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":181586412,"gmtCreate":1623401780336,"gmtModify":1704202615447,"author":{"id":"3578189492032448","authorId":"3578189492032448","name":"DJJJ","avatar":"https://static.tigerbbs.com/7a34f7c7af1d13e4bd21ac607b159890","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578189492032448","authorIdStr":"3578189492032448"},"htmlText":"Totally agree with this article!&nbsp;Just like Buffer who loves saying this -\"Get rich slowly\"&nbsp;[美金]&nbsp;","listText":"Totally agree with this article!&nbsp;Just like Buffer who loves saying this -\"Get rich slowly\"&nbsp;[美金]&nbsp;","text":"Totally agree with this article! Just like Buffer who loves saying this -\"Get rich slowly\" [美金]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181586412","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":181588165,"gmtCreate":1623401679457,"gmtModify":1704202613345,"author":{"id":"3581711485322302","authorId":"3581711485322302","name":"vivo8787","avatar":"https://static.tigerbbs.com/b863ab23ed789e4cdcd83c9777c2cbae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581711485322302","authorIdStr":"3581711485322302"},"htmlText":"Likes&nbsp;","listText":"Likes&nbsp;","text":"Likes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/181588165","repostId":2142221222,"repostType":4,"repost":{"id":"2142221222","kind":"highlight","pubTimestamp":1623380520,"share":"https://ttm.financial/m/news/2142221222?lang=&edition=fundamental","pubTime":"2021-06-11 11:02","market":"us","language":"en","title":"Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing","url":"https://stock-news.laohu8.com/highlight/detail?id=2142221222","media":"Motley Fool","summary":"Get-rich-quick strategies rarely work.","content":"<p>As economist Burton Malkiel, author of the investing classic <i>A</i> <i>Random Walk Down Wall Street</i>, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"</p>\n<p>Investing in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the <b>S&amp;P 500</b> and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.</p>\n<h2>Meme stocks can be speculative binges</h2>\n<p>While you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is <b>Ocugen </b>(NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.</p>\n<p>Without much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least <a href=\"https://laohu8.com/S/AONE\">one</a> dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.</p>\n<p>Despite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&amp;P 500 has risen only 12%. Contrast that with a much safer stock like <b>DexCom</b> (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.</p>\n<h2>Safe investments may be boring, but they don't put you at significant risk</h2>\n<p>Investing in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.</p>\n<p>DexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.</p>\n<p>Similarly, you could buy an ETF like the <b><a href=\"https://laohu8.com/S/IYH\">iShares U.S. Healthcare ETF</a></b>, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.</p>\n<h2>The bottom line</h2>\n<p>Malkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.</p>\n<p>Focusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Making Money in the Stock Market Is Easy -- If You Avoid This 1 Thing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaking Money in the Stock Market Is Easy -- If You Avoid This 1 Thing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 11:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DXCM":"德康医疗","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/10/making-money-in-the-stock-market-is-easy-if-you-av/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142221222","content_text":"As economist Burton Malkiel, author of the investing classic A Random Walk Down Wall Street, says: \"It is not hard to make money in the market. What is hard to avoid is the alluring temptation to throw your money away on short, get-rich-quick speculative binges.\"\nInvesting in the stock market can be as simple or complicated as you make it out to be. You can hand-pick dozens of stocks in your portfolio and aggressively trade every day. You can also hold a single exchange-traded fund (ETF) that mirrors the S&P 500 and hang on to that investment forever. You can make money both ways, although your returns and risk will vary significantly.\nMeme stocks can be speculative binges\nWhile you can certainly make a case for meme stocks being good long-term investments, the temptation for many investors these days is to try and make a significant amount of money in a very short time. And in the near term, stocks can be very erratic. A good example of that is Ocugen (NASDAQ:OCGN). The biotech company only recorded revenue last year for work that it was doing to help fellow biotech Advaite develop a COVID-19 testing kit. And at just $42,620, it was minuscule compared to Ocugen's net losses, which totaled $22 million.\nWithout much of an established business, investors have been speculating on the success of a COVID-19 vaccine candidate, Covaxin, that Ocugen is co-developing with Indian company Bharat Biotech. But even if it's successful, a vaccine may be too little too late, given that half of Americans have already received at least one dose. Under its agreement with Bharat, Ocugen will share in 45% of the profits from vaccine sales in the U.S. market; this has recently been expanded to also include Canada (58% of people there have received at least one dose of a vaccine). Covaxin has not been approved in either market, although Ocugen plans to submit a request for emergency use approval to the U.S. Food and Drug Administration as early as this month.\nDespite what could prove to be limited profits to share, investors are buying up the stock as if it will generate billions in revenue; shares of Ocugen are up over 460% this year, while the S&P 500 has risen only 12%. Contrast that with a much safer stock like DexCom (NASDAQ:DXCM) that generates billions in revenue and posts actual profits -- its shares are up by just 5% in the same time.\nSafe investments may be boring, but they don't put you at significant risk\nInvesting in a medical device company like DexCom -- it's in the business of helping people with diabetes -- is a much safer bet over the long term. Projections from the American Diabetes Association suggest that the disease will be much more prevalent in the future -- the number of diabetes patients in the U.S. in 2000, approximately 11 million, is expected to nearly double to 20 million in 2025. And in 2050 there could be as many as 29 million Americans living with the disease.\nDexCom and its continuous glucose monitoring systems help people stay on top of their glucose levels, and demand for these products will remain strong for the foreseeable future; there isn't much guessing or speculation involved with the business. And while that safety isn't particularly exciting to speculators, investors who are looking to truly make money from the stock market should unquestionably pick DexCom over Ocugen.\nSimilarly, you could buy an ETF like the iShares U.S. Healthcare ETF, which holds many of the top healthcare stocks you'll find on the markets -- no, Ocugen isn't one. Investing in a broad mix of stocks through an ETF spreads out your risk, ensuring your returns won't be dependent on how one single holding performs. That's what makes investing in ETFs even more of a sure thing: As long as their component stocks do well over the long term, your portfolio's value will likely increase over time.\nThe bottom line\nMalkiel mentions in his book that some investors like to make \"castles in the air\" and fantasize about what a company will be in the future, and of course, pay significant premiums based on those incredibly optimistic projections. But many times, fantasy doesn't line up with reality.\nFocusing on stocks that are already profitable, with strong businesses and a clear path to growth, puts you in a great position to profit over the long term -- as long as you resist the urge to gamble on other high-risk investments. And if you aren't comfortable picking your own stocks, you can go with ETFs. Just be careful about speculating -- betting big money on the short term can be incredibly dangerous and costly for your portfolio.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4683860,"gmtCreate":1623403487720,"gmtModify":1663228452462,"authorId":3581711485322302,"author":{"id":3581711485322302,"idStr":"3581711485322302","authorId":3581711485322302,"name":"vivo8787","avatar":"https://static.tigerbbs.com/b863ab23ed789e4cdcd83c9777c2cbae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":181588165,"type":1,"supId":0,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":212,"commentSize":83,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}